• Explore /
  • Poster
  • / Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.

Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.

Abstract Poster

Authors

null

Karthik Rajasekaran

The University of Pennsylvania, Philadelphia, PA

Karthik Rajasekaran , Thomas J Ow , Cherie-Ann Nathan , Alice L Tang , Vikas Mehta , Bradley A Schiff , John Pang , Annemieke Van Zante , Atticus Turner , Marc O Grenley , Connor Burns , Angela Merrell , Emily Beirne , Jonathan Derry , Nathan J Schauer , Jason Frazier , Wendy Jenkins , Richard C. Gregory , Neil Lineberry , Richard Klinghoffer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04541108

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2579)

DOI

10.1200/JCO.2023.41.16_suppl.2579

Abstract #

2579

Poster Bd #

421

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Breakthrough

Investigation of a tamoxifen-RACK7/KDM5C-IFN-I axis for ER<sup>+</sup> breast cancer immunomodulation.

Investigation of a tamoxifen-RACK7/KDM5C-IFN-I axis for ER+ breast cancer immunomodulation.

First Author: Marvin Angelo Esteban Aberin

First Author: Shipra Gandhi

First Author: Valeria Pusceddu

First Author: Pranab Kumar Sahoo